MannKind Corp’s Afrezza Won Recommendations from U.S. Advisory Panel

MannKind Corp’s Afrezza Won Recommendations from U.S. Advisory Panel

After long-waiting for the approval of inhaled diabetes treatment drug, Afrezza, MannKind Corp. finally got recommendation from U. S. advisory panel. The panel of Food and Drug Administration (FDA) advisers has voted 13 in favor of recommending the drug for treating Type 1 and Type 2 diabetes.

Earlier, two times rejection of the MannKind's inhaled diabetes drug in 2011 and the release of Pfizer Inc's inhaled diabetes drug, Exubera, in 2006, caused the company to witness steep decrease in its shares from 21.70 to $1.60. But, the Pfizer Inc's Exubera later on faced setback as the drug showed increased risk of lung cancer because the insulin was directly deposited in the lungs.

Despite of recommendation from advisory panel, FDA raised the same concern claiming the Afrezza may cause lung function. Moreover, they added that the drug contains some missing information from the study conducted on Type 1 patients.

Alfred Mann, 88-year-old founder, chairman, chief executive officer and largest shareholder of the Company, said his company feels pleased on the approval recommendation of the Afrezza.

Diabetes is a major health problem in the U. S. and the development of the novel drug would prove successful in treating patients without following insulin injections, said Alfred.

According to statistical report by the Centers for Disease Control and Prevention (CDC), about 26 million people were suffering with diabetes in U. S. in 2010 and declared the disease as the seventh-leading cause of death in the U. S.

About 90% to 95% of deaths in U. S. are caused by Type 2 diabetes, according to sources. The average estimate by three analysts has revealed that the approval of the drug by the FDA, which will be declared by April 15, is expected to generate revenue of $534 million in 2018.


FrenchTribune Specials

Google persuading Firefox users to ditch Yahoo as their default search engine

In an apparent effort to retain its dominance in the Internet search arena, Google is trying to convince the US users of Mozilla’s Firefox browser to ditch Yahoo as their default search engine, and switch to Google Search.

Google’s attempts underscore a move by the company to win back Firefox users, after a November deal between Mozilla...

Most Popular

Accurate position of Saturn and its moons formulated by NASA

The pains taken by NASA researchers have paid in a huge...

Lost Memories Can Be Renewed, Says New UCLA Brain Research

An all-new study by the researchers of the University of...

Poll

Can Greece Come out of Economic Problems: